Needs assessment for creation of a platform trial network in metabolic-dysfunction associated steatohepatitis.

While preliminary, our findings on responding sites are encouraging for the potential establishment of a CRN for a MASH IRP. However, funding schemes and sustainability strategies to provide proof-of-platform in MASH seem key in the short-term scenario.